Ignite Creation Date:
2025-12-24 @ 11:00 PM
Ignite Modification Date:
2026-01-01 @ 8:34 AM
Study NCT ID:
NCT01067469
Status:
COMPLETED
Last Update Posted:
2020-03-17
First Post:
2010-02-10
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)
Sponsor:
M.D. Anderson Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2010-01
Start Date Type:
None
Primary Completion Date:
2016-10
Primary Completion Date Type:
ACTUAL
Completion Date:
2016-10
Completion Date Type:
ACTUAL
First Submit Date:
2010-02-10
First Submit QC Date:
None
Study First Post Date:
2010-02-11
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2020-01-22
Results First Submit QC Date:
None
Results First Post Date:
2020-03-17
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-03-10
Last Update Post Date:
2020-03-17
Last Update Post Date Type:
ACTUAL